ESR1 and neoplasm: Tamoxifen is the standard anti-ER therapeutic agent for breast cancer (approved by FDA) in the neoadjuvant as well as adjuvant settings [4], [5]; tamoxifen reduces tumor size in responding patients to facilitate conservation surgery without affecting survival, and it decreases the recurrence rate up to 50% regardless of menopausal status.